Composition containing V-type collagen peptide, preparation method of composition and application of composition in eye protection products

Abstract

The invention provides a composition containing V-type collagen peptide, a preparation method of the composition and application of the composition in eye protection products, and belongs to the field of bioactive peptides. The composition at least comprises a V-type collagen peptide, a jack fruit peptide and a pleurotus citrinopileatus extract in a weight ratio of (30-50): (10-20): (2-5), and the three components are combined to achieve a good removal effect on the active oxygen level of human retina microcirculation endothelial cells and have a certain synergistic effect. Other bioactive peptides and other raw materials are also compounded in the composition, and a good active oxygen scavenging effect is also achieved. The composition provided by the invention is proved to be effective and safe in relieving visual fatigue through verification of people, and has a very good application prospect.

Description

Technical Field

[0001] The invention belongs to the field of bioactive peptides, and specifically relates to a composition containing type V collagen peptides, a preparation method thereof, and an application of the composition in eye protection products. Background Art

[0002] With the development of science and technology and the popularization of electronic products, people are becoming more and more dependent on monitors in their daily lives and work. Staring at the screens of computers, mobile phones, tablets, etc. for a long time for work or entertainment will keep the eyes in a state of tension for a long time, and the eye muscles will remain contracted for a long time without sufficient rest, which will cause eye fatigue. In addition, bad eye habits, such as reading or writing for a long time, or using the eyes in an environment with too dark or too strong light, will increase the burden on the eyes and cause eye fatigue.

[0003] Eye fatigue not only affects personal visual function, but also causes a series of health problems. Long-term visual fatigue may cause retinal damage, which in turn may lead to retinal diseases such as retinal tears and retinal detachment. In addition, eye fatigue can also affect sleep quality, cause headaches, dizziness and other discomfort symptoms, and affect the quality of life.

[0004] The pathophysiological mechanisms of eye fatigue include overuse of eye muscles, damage to retinal cells, increased oxidative stress, imbalance of the tear system, and disruption of the biological clock. The combined effects of these multiple factors together lead to symptoms of eye fatigue, affecting people's visual function and quality of life.

[0005] Currently, the treatments for eye fatigue on the market are mainly eye drops or lutein soft capsules, and there are basically no bioactive peptide-related compositions. Bioactive peptides have many positive effects in relieving eye fatigue. They provide biological intervention strategies by improving microcirculation, anti-oxidation, promoting repair, and regulating energy metabolism. These findings provide a theoretical basis for the development of new eye care products and therapies, and are expected to become an effective means of preventing and treating eye fatigue in the future. Summary of the invention

[0006] In order to solve the above problems, the present invention provides a composition containing type V collagen peptide, which is a composition containing bioactive peptides and can effectively relieve visual fatigue and reduce oxidative stress of retinal cells.

[0007] In one aspect, the present invention provides a composition comprising type V collagen peptide.

[0008] The composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 30-50:10-20:2-5.

[0009] Preferably, the composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 35-45:12-18:3-5.

[0010] Further preferably, the composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 30-45:15-18:4-5.

[0011] Furthermore, the composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 40-45:15-18:5.

[0012] In some specific embodiments, the composition may include: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 40:16:5 or 35:15:4 or 45:18:5.

[0013] On the basis of the above-mentioned composition, the composition may also selectively include any one or more of bovine liver peptide, Antarctic krill oil microcapsule powder, wolfberry peptide, and cassia seed peptide.

[0014] Preferably, the composition also includes wolfberry peptide and cassia seed peptide; the weight ratio of the components in the composition can be: V-type collagen peptide: jackfruit peptide: Pleurotus eryngii extract: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 20-30: 5-8; as an example, the weight ratio of the components in the composition can be: V-type collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 25-30: 5-8.

[0015] Further preferably, the composition also includes bovine liver peptide; the weight ratio of each component in the composition can be: V-type collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 10-20: 20-30: 5-8; further, the weight ratio of each component in the composition can be: V-type collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 15-20: 25-30: 5-8.

[0016] Further preferably, the composition also includes Antarctic krill oil microcapsule powder; the weight ratio of the components in the composition can be: V-type collagen peptide: jackfruit peptide: golden top pleurotus eryngii extract: Antarctic krill oil microcapsule powder, wolfberry peptide, cassia seed peptide = 30-45: 15-18: 4-5: 10-20: 20-30: 5-8; further, the weight ratio of the components in the composition can be: V-type collagen peptide: jackfruit peptide: golden top pleurotus eryngii extract: Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide = = 30-45: 15-18: 4-5: 15-20: 25-30: 5-8.

[0017] Further preferably, the composition also includes bovine liver peptide and Antarctic krill oil microcapsule powder; the weight ratio of the components in the composition can be: type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: Antarctic krill oil microcapsule powder: wolfberry peptide: Cassia seed peptide = 30-45: 15-18: 4-5: 10-20: 10-20: 20-30: 5-8; further, the weight ratio of the components in the composition can be: 30-45: 15-18: 4-5: 15-20: 15-20: 25-30: 5-8.

[0018] In another aspect, the present invention provides a method for preparing the aforementioned composition.

[0019] Based on the aforementioned ratio, the preparation method provided by the present invention at least includes mixing the raw materials in proportion.

[0020] Preferably, the preparation method of the present invention may also include a preparation method of any raw material; such as a preparation method of any one of type V collagen peptide, jackfruit peptide, Pleurotus eryngii extract, bovine liver peptide, Antarctic krill oil microcapsule powder, wolfberry peptide, and cassia seed peptide.

[0021] As an example, a method for preparing a raw material is provided, including a method for preparing type V collagen peptide as follows:

[0022] S1: Select animal eyes as raw materials and crush the raw materials;

[0023] S2: Pretreatment: vacuum degassing treatment;

[0024] S3: Enzymatic hydrolysis: the first enzymatic hydrolysis uses lipase from Aspergillus niger, and the second enzymatic hydrolysis uses protease, which is mixed with pineapple juice stock solution;

[0025] S4: After the enzyme is inactivated, the mixture is allowed to stand and separated into layers, and the lower layer of liquid is the raw material for type V collagen peptide;

[0026] S5: Post-processing: flocculating, filtering, decolorizing, nanofiltration, vacuum concentration, degassing and deodorizing, sterilizing, and drying the raw materials obtained in S4.

[0027] Preferably, the method for preparing the type V collagen peptide is as follows:

[0028] (1) The raw material is the eyes of livestock, poultry or fish (frozen or fresh); crushing: crushing into soybean size using a crusher;

[0029] (2) Pretreatment: 80-90°C, vacuum degassing for 20-60 min; vacuum degree -0.08 to -0.1 MPa;

[0030] (3) Primary enzymatic hydrolysis: cooling to 35-45°C, pH 6.0-8.0, adding 0.01-0.1% of the weight of the raw material lipase from Aspergillus niger, and enzymatic hydrolysis for 1.5-3h;

[0031] (4) Secondary enzymatic hydrolysis: heating to 50-60° C., adding 0.1%-0.3% of protease by weight of the raw material, with the ratio of protease to pineapple juice stock solution (mass ratio) = 1:5-10, and performing enzymatic hydrolysis for 2-5 hours;

[0032] (5) Enzyme inactivation: 80-90°C, 10-20 min; preferably 85°C, 15 min;

[0033] (6) Standing: After the enzyme is inactivated, the mixture is allowed to stand for 30 min to 2 h, preferably 1 to 2 h.

[0034] (7) Stratification: The upper layer of oil is separated for oil processing (disc separation + tubular centrifugation) as a by-product of the product, and the lower layer of liquid is used as the raw material 1 of type V collagen peptide;

[0035] (8) Flocculation: Add 0.3%-0.8% of the liquid weight of raw material 1 diatomaceous earth and 0.01%-0.6% of the solid dry weight of deacetylated chitosan clarifier, dissolve in water before use, stir for 2-10 minutes after adding, and then let stand for 20 minutes to 2 hours;

[0036] (9) Filtration: The supernatant was filtered by a disc centrifuge at a speed of 6000 r / h and the slag was discharged once every 300 seconds;

[0037] (10) Activated carbon decolorization: add 2%-10% of the dry weight of the raw material activated carbon, 60-75°C, decolorize for 40 minutes; preferably 3%-6% activated carbon, 60°C, decolorize for 40 minutes;

[0038] (11) Nanofiltration: pre-concentration to 15%-25%, preferably 15%-20%;

[0039] (12) Vacuum concentration: concentrated to 35%-50%; preferably 35%-43%;

[0040] (13) Degassing and deodorization: vacuum degassing and deodorization, 60°C, decolorization for 30 min, vacuum degree -0.08 to -0.1 MPa;

[0041] (14) Sterilization: sterilization by UHT (121±3℃, 10-20s) or 0.45+0.22μm membrane sterilization, or pulse sterilization;

[0042] (15) Drying: Drying is carried out by spray drying or vacuum belt drying.

[0043] In some specific embodiments:

[0044] The pretreatment in step (2) is preferably performed at 80-85°C for 20-40 minutes;

[0045] In the step (3), the temperature of the enzymatic hydrolysis is preferably lowered to 35-40° C., pH 7.0-8.0, and 0.05-0.1% by weight of the raw material of lipase derived from Aspergillus niger is added, and the enzymatic hydrolysis is carried out for 2 hours.

[0046] The protease in step (4) is preferably a protease derived from Bacillus subtilis. In actual production, Xiasheng FDY-2241 sold by Ningxia Xiasheng Industrial Group Co., Ltd. can be selected.

[0047] The method for preparing the pineapple juice stock solution in step (4) is as follows: fresh pineapples grown for 15±1 months are directly squeezed for juice, and then filtered through a sieve with 80+300 meshes, and then directly put into use, and the juice is prepared within 1 hour before use.

[0048] The secondary enzymatic hydrolysis in step (4) is preferably performed at 53-58° C., 0.15-0.25% protease, the ratio of protease to pineapple juice (mass ratio) is 1:6-8, and the enzymatic hydrolysis time is 3-4 hours.

[0049] In the step (8), preferably 0.4-0.5% diatomaceous earth and 0.25-0.5% chitosan are used, and the mixture is preferably stirred for 2-5 minutes and allowed to stand for 40-60 minutes.

[0050] The type V collagen peptide has the following characteristics: it has specific peptide segments: GPPGP*P*GEGLP*GLA; GDP*GTVGPP*GP*; and it is also found that the type V collagen peptide product also contains type I, type II and type III peptide segments, and the results are as follows:

[0051]

[0052]

[0053] Note: * represents hydroxylation modification.

[0054] The molecular weight of type V collagen peptide is 800-1500Da, the product contains more than 1.0% mucopolysaccharide, and under the conditions of pH 3.0-5.0, 80-90°C, 20min-2h, 5%-60% has no precipitation.

[0055] In another aspect, the present invention provides an application of the aforementioned composition, characterized in that the application is selected from the following:

[0056] (1) preparing eye protection products;

[0057] or (2) preparing a product for preventing discomfort symptoms caused by eye fatigue.

[0058] Preferably, the eye protection product is used to prevent or alleviate eye problems such as visual fatigue, retinal damage, retinal holes, and retinal detachment.

[0059] Preferably, the discomfort symptoms include but are not limited to: poor sleep quality, headache, and dizziness.

[0060] In yet another aspect, the present invention provides an eye protection product comprising the aforementioned composition.

[0061] The product can be food, health care product or medicine.

[0062] The product may also include auxiliary materials commonly used in the art, but there is no limitation on the types of auxiliary materials.

[0063] For example, when the product is a food, it may include raw materials commonly used in the food field, such as: flavoring agents, colorants, fillers, disintegrants, sweeteners, lubricants, adhesives, pH adjusters, etc.

[0064] For example, when the product is a medicine, it may include pharmaceutically acceptable excipients, such as excipients, buffers, emulsifiers, stabilizers, diluents, adhesives, preservatives, lubricants, controlled release agents, cross-linking agents, etc.

[0065] Specifically, the excipient is selected from at least one of microcrystalline cellulose, lactose, pregelatinized starch, cyclodextrin, carboxymethyl cellulose and mannitol.

[0066] Specifically, the buffer is selected from at least one of sodium dihydrogen phosphate, sodium bicarbonate, ammonium bicarbonate, sodium acetate, citrate, histidine, and succinate.

[0067] Specifically, the emulsifier is selected from at least one of magnesium stearate, zinc stearate, calcium stearate, glyceryl stearate, sorbitan isostearate, sorbitan oleate, glyceryl oleate, and polyglycerol 3 polyricinoleate.

[0068] Specifically, the stabilizer is selected from at least one of acacia gum, agar, alginic acid, cellulose ether, and carboxymethyl chitosan.

[0069] Specifically, the diluent is selected from at least one of erythritol, mannitol, sorbitol, xylitol, lactose, sucrose, corn starch, potato starch, calcium phosphate, calcium citrate, and crystalline cellulose.

[0070] Specifically, the adhesive is selected from at least one of ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, and polyvinyl pyrrolidone.

[0071] Specifically, the preservative is selected from at least one of methyl paraben, propyl paraben, methyl paraben, ethyl paraben, propyl paraben, chlorobutanol, thimerosal, mercuric cyanide, phenoxyethanol, chlorhexidine, benzoic acid, sodium benzoate, chlorocresol, benzalkonium bromide, benzalkonium chloride, and ethyl paraben.

[0072] Specifically, the lubricant is selected from at least one of magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, and poloxamer.

[0073] Beneficial effects of the present invention:

[0074] The present invention verifies its application in eye protection by compounding a composition containing type V collagen peptide. The composition of the present invention includes at least type V collagen peptide, jackfruit peptide and golden top pleurotus extract. The combination of the three has a good scavenging effect on the level of active oxygen in human retinal microcirculation endothelial cells, and there is a certain synergistic effect. On the basis of the above, other raw materials such as bioactive peptides are also compounded in the composition of the present invention, which also achieves a good active oxygen scavenging effect. And the composition provided by the present invention has been verified by the population, proving its effectiveness and safety in relieving visual fatigue, and has a good application prospect. BRIEF DESCRIPTION OF THE DRAWINGS

[0075] Figure 1 Effects of reactive oxygen species probe fluorescence detection composition on ROS in cell oxidative damage model. DETAILED DESCRIPTION

[0076] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0077] All formula raw materials in the implementation case are provided by Beijing Shengminuo Biotechnology Co., Ltd. The relevant purchase information is as follows:

[0078] name brand Part Number Type V collagen peptide Beijing Shengminuo Biotechnology Co., Ltd. 20240628-S Jackfruit peptide Beijing Shengminuo Biotechnology Co., Ltd. 20230622-1 Pleurotus eryngii extract Beijing Shengminuo Biotechnology Co., Ltd. 20240316-S Bovine liver peptide Beijing Shengminuo Biotechnology Co., Ltd. 20240403-1 Lycium barbarum peptide Beijing Shengminuo Biotechnology Co., Ltd. 20240127-1 Cassia seed peptide Beijing Shengminuo Biotechnology Co., Ltd. 20240701-S Antarctic krill oil microencapsulated powder Qingdao Antarctic Weikang Biotechnology Co., Ltd. 20240506-G

[0079] Examples 1-4 provide different formulations of compositions containing type V collagen peptides, and the preparation method is to mix the raw materials according to the ratio. The specific formulations of Examples 1-4 are as follows:

[0080] Example 1

[0081] Servings by weight include:

[0082] Type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract = 40:16:5.

[0083] Example 2

[0084] Servings by weight include:

[0085] Type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: wolfberry peptide: cassia seed peptide = 40:16:5:15:25:8.

[0086] Example 3

[0087] Servings by weight include:

[0088] Type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: Antarctic krill oil microcapsule powder, wolfberry peptide, cassia seed peptide = 35:15:4:15:25:5.

[0089] Example 4

[0090] Servings by weight include:

[0091] Type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide, Antarctic krill oil microcapsule powder, wolfberry peptide, cassia seed peptide = 45:18:5:20:20:30:8.

[0092] Comparative Examples 1-9 set formulations different from those of the embodiments, as follows:

[0093] Comparative Example 1

[0094] Servings by weight include:

[0095] Beef liver peptide: wolfberry peptide: cassia seed peptide = 15:25:8.

[0096] Comparative Example 2

[0097] Servings by weight include:

[0098] Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide = 15:25:5.

[0099] Comparative Example 3

[0100] Servings by weight include:

[0101] Beef liver peptide: Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide = 20:20:30:8.

[0102] Comparative Example 4

[0103] Servings by weight include:

[0104] Jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide = 18:5:20:20:30:8.

[0105] Comparative Example 5

[0106] Servings by weight include:

[0107] Type V collagen peptide: Pleurotus eryngii extract: bovine liver peptide, Antarctic krill oil microcapsule powder, wolfberry peptide, cassia seed peptide = 45:5:20:20:30:8.

[0108] Comparative Example 6

[0109] Servings by weight include:

[0110] Type V collagen peptide: jackfruit peptide: bovine liver peptide, Antarctic krill oil microcapsule powder, wolfberry peptide, cassia seed peptide = 45:18:20:20:30:8.

[0111] Comparative Example 7

[0112] Includes Type V collagen peptides only.

[0113] Comparative Example 8

[0114] Includes only jackfruit peptides.

[0115] Comparative Example 9

[0116] Only Pleurotus eryngii extract was included.

[0117] The efficacy experiments were conducted on the products provided in the embodiments and comparative examples, as follows:

[0118] Efficacy experiment 1 Effect of the composition on the level of reactive oxygen species in human retinal microcirculatory endothelial cells

[0119] After the cells (human retinal microcirculatory endothelial cells Cat No.: JY-J101: Shanghai Jinyuan Biotechnology Co., Ltd.) were spread on the plate, the cells were collected into a 10 mL centrifuge tube, centrifuged at 1200 rpm for 3 min, the supernatant was removed, new cell culture medium was added, pipetted evenly, and counted using a hemocytometer. 10 cells were spread into each well of a 96-well plate. 4 cells, with a total volume of 200 μL, and cultured overnight at 37°C and 5% CO2. Then, the cells were treated with a composition with a final concentration of 800 μg / mL for 12 hours, 4 replicates were set for each group, and a blank group and a positive control group were set at the same time. Then, the cells were treated with 600 μM hydrogen peroxide for 1 hour, and the cells were washed twice with PBS. Then, the culture solution containing 10 μM DCFH-DA fluorescent probe was added to load the probe for 30 minutes, and the excess probe was washed twice with PBS to remove it. The fluorescence intensity was detected using a fluorescence microplate reader at an excitation wavelength of 488 nm and an emission wavelength of 525 nm.

[0120] The results are as follows Figure 1 As shown, from Figure 1 The results show that: the cells were pretreated with each composition at a concentration of 800 μg / mL for 12 h, and then the cells were treated with 600 μM hydrogen peroxide for 1 h. Each composition significantly reduced the ROS level in the cells, and it was found that the scavenging ability of type V collagen peptide, jackfruit peptide or Pleurotus eryngii extract alone was not as good as the mixed effect. Specifically, it can be seen from Example 1 and Comparative Examples 1-9 that when the total dose is the same, the mixed application of type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract has a better scavenging effect on the active oxygen level of human retinal microcirculation endothelial cells, indicating that there is a synergistic effect between the components of the combined application of the three. In addition, it can be seen from Examples 1-4 that by mixing the above three raw materials and then adding some other active peptides, a better active oxygen scavenging effect can be achieved, and there is a synergistic effect between the components. Specifically: (1) It can be seen from Examples 1-2 and Comparative Example 1 that under the same total dose and the same ratio, the overall effect of Example 2 is better than that of Example 1 and Comparative Example 1, indicating that when the two components of Example 1 and Comparative Example 1 constitute the whole of Example 2, there is a synergistic effect of scavenging active oxygen between the components; (2) It can be seen from Example 1, Example 3 and Comparative Example 2 that under the same total dose and the same ratio, there is also a synergistic effect similar to the above between the overall components of Example 3; (3) Through Example 1, Example 4 and Comparative Example 3, the synergy of the components in Example 4 is reflected.

[0121] Efficacy experiment 2: Experiment on relieving visual fatigue

[0122] This efficacy experiment was conducted using the example group (Example 4) with the strongest ability to clear ROS from cells, and product function evaluation tests and other work were carried out in accordance with the "Health Food Function Test and Evaluation Method (2023 Edition)".

[0123] To observe the effectiveness and safety of taking eye protection combination products in relieving visual fatigue;

[0124] 1. Subjects: Adults aged 18-65 years old;

[0125] Subject exclusion criteria:

[0126] Patients with infectious or traumatic eye diseases. Those who have undergone eye surgery within 3 months;

[0127] Patients with internal and external eye diseases such as corneal, lens, vitreous, and fundus lesions;

[0128] People with cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other diseases;

[0129] Pregnant or lactating women, patients with allergies;

[0130] Taking items related to the function being tested in the short term may affect the judge of the results;

[0131] Those who have been taking vision-related medications, health products or other treatments for a long time and have not been able to stop;

[0132] Those who do not meet the inclusion criteria, do not consume the test substance as required, or have incomplete information that affects the judgment of efficacy or safety.

[0133] 2. Experimental method: randomized double-blind controlled trial design;

[0134] 3. Experimental grouping: The subjects were randomly divided into a test group and a control group. The test group had 60 subjects who took the composition of Example 4 orally, 6 g per day, for 2 months; the control group had 60 subjects who took a placebo group (without any component of the composition and components known to relieve visual fatigue) orally, 6 g per day, for 2 months.

[0135] 4. Observation indicators

[0136] 4.1 Safety indicators:

[0137] 4.1.1 Routine blood and urine examination, physical examination.

[0138] 4.1.2 Liver and kidney function tests.

[0139] 4.1.3 Chest X-ray, electrocardiogram, and abdominal B-ultrasound examination (one examination before the food tasting).

[0140] 4.2 Efficacy indicators: Check at the beginning and end of the trial.

[0141] 4.2.1 Questionnaire survey: symptom inquiry and eye use.

[0142] 4.2.2 Ophthalmological examination: including fundus examination, vision examination (myopia, hyperopia, astigmatism, etc.).

[0143] 4.2.3 Durability of clear vision.

[0144] 5. Efficacy Criteria

[0145] 5.1 Effectiveness of symptom improvement

[0146] Symptoms were considered improved when 3 out of 8 symptoms including eye pain, eye swelling, photophobia, blurred vision, dry eyes, foreign body sensation, tearing, and general discomfort were improved, and other symptoms did not worsen. The number of symptom improvement cases in the two groups and the symptom improvement efficiency of the two groups were calculated. The symptom improvement efficiency (%) was calculated as the number of symptom improvement cases / the number of trial cases × 100. The symptom improvement efficiency of the two groups was statistically tested. The method for determining visual fatigue symptoms (semi-quantitative integration method) is as follows:

[0147]

[0148] Note: “Occasionally” means 1-2 times / 2 days; “Sometimes” means 1-3 times / day; “Often” means >3 times / day.

[0149] The results of the improvement rate of each symptom are shown in Table 1 below:

[0150] Table 1

[0151]

[0152] According to the judgment criteria, it can be seen from the above table that the embodiment group is effective in relieving visual fatigue, but the placebo group has only slight improvements in two indicators, which is considered ineffective according to the judgment criteria.

[0153] 5.2 Persistence of Vision

[0154] There was a significant difference in the persistence of visual acuity between the trial group and the control group (P<0.05), and the improvement of the average persistence of visual acuity by 10% or more was considered effective.

[0155] The results of improvement in visual persistence are shown in Table 3:

[0156] Table 3

[0157] Group Before tasting After tasting Increase the ratio Example 4 0.56±0.06 0.73±0.08** 30.4％ Placebo group 0.55±0.05 0.56±0.06 1.8％

[0158] “**” indicates P < 0.01 compared with before the trial.

[0159] It can be seen from Table 3 that the embodiment group improves the efficiency by more than 10%, which proves that it is effective in alleviating visual fatigue.

[0160] Based on the above data, according to the product function evaluation test judgment standards of the "Health Food Function Test and Evaluation Method (2023 Edition)", it can be seen that the composition of Example 4 has the effect of relieving visual fatigue.

Claims

1. A composition containing type V collagen peptide, characterized in that: The composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 30-50:10-20:2-5.

2. The composition according to claim 1, characterized in that The composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 35-45:12-18:3-5.

3. The composition according to claim 2, characterized in that The composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 35-45:15-18:4-5.

4. The composition according to claim 3, characterized in that The composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 40-45:15-18:

5.

5. The composition according to claim 4, characterized in that The composition comprises: type V collagen peptide, jackfruit peptide and Pleurotus eryngii extract in a weight ratio of 40:16:5 or 35:15:4 or 45:18:

5.

6. The composition according to claim 1, characterized in that The composition further comprises any one or more of bovine liver peptide, Antarctic krill oil microcapsule powder, wolfberry peptide and cassia seed peptide.

7. The composition according to claim 6, characterized in that The composition also includes wolfberry peptide and cassia seed peptide.

8. The composition according to claim 7, characterized in that It also includes bovine liver peptide; the weight ratio of each component in the composition is: type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 10-20: 20-30: 5-8.

9. The composition according to claim 8, characterized in that The weight ratio of each component in the composition is: type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 15-20: 25-30: 5-8.

10. The composition according to claim 7, characterized in that It also includes Antarctic krill oil microcapsule powder; the weight ratio of the components in the composition is: type V collagen peptide: jackfruit peptide: golden top pleurotus eryngii extract: Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 10-20: 20-30: 5-8.

11. The composition according to claim 10, characterized in that The weight ratio of each component in the composition is: type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide==30-45:15-18:4-5:15-20:25-30:5-8.

12. The composition according to claim 7, characterized in that The composition also includes bovine liver peptide and Antarctic krill oil microcapsule powder. The weight ratio of the components in the composition is: type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 10-20: 10-20: 20-30: 5-8.

13. The composition according to claim 12, characterized in that The weight ratio of each component in the composition is: type V collagen peptide: jackfruit peptide: Pleurotus eryngii extract: bovine liver peptide: Antarctic krill oil microcapsule powder: wolfberry peptide: cassia seed peptide = 30-45: 15-18: 4-5: 15-20: 15-20: 25-30: 5-8.

14. A method for preparing the composition according to any one of claims 1 to 13, characterized in that: Involves mixing the raw materials in proportion.

15. The preparation method according to claim 14, characterized in that: Also included is a method for preparing any raw material; The preparation method of the raw materials includes a preparation method of type V collagen peptide; The preparation method of the type V collagen peptide comprises: S1: Select animal eyes as raw materials and crush the raw materials; S2: Pretreatment: vacuum degassing treatment; S3: Enzymatic hydrolysis: the first enzymatic hydrolysis uses lipase from Aspergillus niger, and the second enzymatic hydrolysis uses protease, which is mixed with pineapple juice stock solution; S4: After the enzyme is inactivated, the mixture is allowed to stand and separated into layers, and the lower layer of liquid is the raw material for type V collagen peptide; S5: Post-processing: flocculating, filtering, decolorizing, nanofiltration, vacuum concentration, degassing and deodorizing, sterilizing, and drying the raw materials obtained in S4.

16. Use of the composition according to any one of claims 1 to 13, characterized in that: The application is selected from the following: (1) preparing eye protection products; or (2) preparing a product for preventing discomfort symptoms caused by eye fatigue.

17. The use according to claim 16, characterized in that The eye protection product is used to prevent or alleviate: visual fatigue, retinal damage, retinal holes, retinal detachment; the discomfort symptoms include: poor sleep quality, headache, and dizziness.

18. An eye protection product comprising the composition of any one of claims 1 to 13.

Images